ABSTRACT
Background Severe traumatic brain injury (TBI) frequently disrupts cerebral autoregulation, rendering cerebral perfusion pressure highly dependent on systemic hemodynamics. Vasopressors are a cornerstone of TBI management, yet norepineph-rine and vasopressin may exert divergent effects on cerebral autoregulation and systemic cardiovascular function. Their comparative impact in this population remains poorly defined.
Objective The REGULATE trial is a randomized, controlled study designed to investigate the effects of norepinephrine, vasopressin, and their combination on cerebral autoregulation and advanced systemic hemodynamics in patients with severe TBI.
Methods This quadruple-blinded, parallel-group trial will enroll 450 adults with severe TBI (Glasgow Coma Scale ≤ 8) requiring vasopressor support. Participants will be randomized (1:1:1) to norepinephrine, vasopressin, or combination therapy. Continuous multimodal monitoring will include intracranial pressure, arterial pressure, near-infrared spectroscopy, and advanced cardiac output assessment. Co-primary outcomes are (1) cerebral autoregulation, quantified as the area under the curve of the pressure reactivity index over 48 hours, and (2) systemic hemodynamics, defined as the area under the curve of cardiac output and effective arterial elastance over 48 hours. A prespecified interaction analysis will evaluate treatment effects on the relationship between cerebral autoregulation and systemic hemodynamics. Secondary outcomes include cerebral oxygenation indices, intracranial pressure burden, vasopressor dose exposure, organ perfusion markers, adverse events, and clinical outcomes (mortality, ICU length of stay, neurological recovery at 3 months).
Conclusions REGULATE is the first adequately powered trial to systematically compare norepinephrine, vasopressin, and their combination on cerebral autoregulation and systemic cardiovascular performance in severe TBI. Results are expected to inform individualized vasopressor strategies to optimize cerebral and systemic physiology while minimizing secondary injury.
Trial registration ClinicalTrials.gov (forthcoming).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study will be registered at ClinicalTrials.gov
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval will be provided by the Ethics Committee of the Tzaneio General Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
